Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holly M Nguyen

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Journal of Oncology|October 23, 2019
Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular CarcinomaAndrew D Ludwig, Kevin P Labadie, Y David Seo, et al.
Plos One|November 9, 2013
Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodelingHolly M Nguyen, Nazanin Ruppender, Xiaotun Zhang, et al.
Scientific Reports|June 26, 2021
MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancerEn-Chi Hsu, Michelle Shen, Merve Aslan, et al.
Molecular Cancer Therapeutics|February 15, 2020
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer ModelsUlrike Weyer-Czernilofsky, Marco H Hofmann, Katrin Friedbichler, et al.
The Journal of Clinical Investigation|July 21, 2010
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variantShihua Sun, Cynthia C T Sprenger, Robert L Vessella, et al.
Journal of Cellular Physiology|January 17, 2016
Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by ReprogrammingGisely T Borges, Eneida F Vêncio, Sue-Ing Quek, et al.
Endocrinology|May 15, 2013
5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal modelsKhalid Z Masoodi, Raquel Ramos Garcia, Laura E Pascal, et al.
British Journal of Cancer|October 5, 2023
ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotypeMichelle Shen, Shiqin Liu, Angus Toland, et al.
Scientific Reports|February 26, 2021
A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid cultureElise Y Cai, Jose Garcia, Yuzhen Liu, et al.
The Prostate|February 4, 2017
LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer TherapeuticsHolly M Nguyen, Robert L Vessella, Colm Morrissey, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Journal of Oncology|October 23, 2019
Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular CarcinomaAndrew D Ludwig, Kevin P Labadie, Y David Seo, et al.
Plos One|November 9, 2013
Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodelingHolly M Nguyen, Nazanin Ruppender, Xiaotun Zhang, et al.
Scientific Reports|June 26, 2021
MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancerEn-Chi Hsu, Michelle Shen, Merve Aslan, et al.
Molecular Cancer Therapeutics|February 15, 2020
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer ModelsUlrike Weyer-Czernilofsky, Marco H Hofmann, Katrin Friedbichler, et al.
The Journal of Clinical Investigation|July 21, 2010
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variantShihua Sun, Cynthia C T Sprenger, Robert L Vessella, et al.
Journal of Cellular Physiology|January 17, 2016
Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by ReprogrammingGisely T Borges, Eneida F Vêncio, Sue-Ing Quek, et al.
Endocrinology|May 15, 2013
5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal modelsKhalid Z Masoodi, Raquel Ramos Garcia, Laura E Pascal, et al.
British Journal of Cancer|October 5, 2023
ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotypeMichelle Shen, Shiqin Liu, Angus Toland, et al.
Scientific Reports|February 26, 2021
A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid cultureElise Y Cai, Jose Garcia, Yuzhen Liu, et al.
The Prostate|February 4, 2017
LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer TherapeuticsHolly M Nguyen, Robert L Vessella, Colm Morrissey, et al.
Pageof 5